MedTrace Logo

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05989711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2026-05-18

No results posted yet for this study

Summary

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Conditions

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

DRUG

Pemvidutide

Administered once weekly by subcutaneous injection

DRUG

Placebo

Administered once weekly by subcutaneous injection

Sponsors & Collaborators

  • Altimmune, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-27
Primary Completion
2025-11-25
Completion
2025-11-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05989711 on ClinicalTrials.gov